Effect of Pollypill on cardiovascular parameters: Systematic review and meta-analysis

Journal of Cardiovascular Disease Research

Volumn 4, Issue 2, 2013, Pages 92-97

  Charan, Jaykaran ^a   Goyal, Jagdish Prasad ^b   Saxena, Deepak ^c  

^a GOVERNMENT MEDICAL COLLEGE   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c Indian Institute of Public Health   (India)

Author keywords

Clinical trials; Diastolic blood pressure; Low density lipoprotein cholesterol; Pollypill; Systolic blood pressure

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN CONVERTING ENZYME INHIBITOR PLUS ASPIRIN PLUS BETA BLOCKER PLUS HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ATENOLOL; CARDIOVASCULAR AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HEART RATE; HUMAN; LOW DRUG DOSE; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

EID: 84880511161     PISSN: 09753583     EISSN: 09762833     Source Type: Journal    
DOI: 10.1016/j.jcdr.2012.11.005     Document Type: Article

References (19)

1. World Health Organization Preventing Chronic Diseases: A Vital Investment. WHO Global Report 2005 Available from: http://www.who.int/chp/ chronic-disease-report/en/ [Last Accessed on 18.09.12]
2. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
3. C. Baigent, A. Keech, and P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 patients in 14 randomized trials of statins Lancet 366 2005 1267 1278
4. B.M. Psaty, T. Lumley, and C.D. Furberg Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis JAMA 289 2003 2534 2544
5. S.P. Kulkarni, K.P. Alexander, B. Lytle, G. Heiss, and E.D. Peterson Long-term adherence with cardiovascular drug regimens Am Heart J 151 2006 185 191
6. E. Lonn, J. Bosch, K.K. Teo, P. Pais, D. Xavier, and S. Yusuf The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions Circulation 122 2010 2078 2088
7. N.J. Wald, and M.R. Law A strategy to reduce cardiovascular disease by more than 80% BMJ 326 2003 1419
8. L.W. Green Prospects and possible pitfalls of a preventive polypill: confessions of a health promotion convert Eur J Clin Nutr 59 suppl 1 2005 S4 S8
9. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration PLoS Med 6 2009 e1000100
10. The Indian Polycap Study (TIPS) S. Yusuf, P. Pais, and R. Afzal Effects of a polypill (polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial Lancet 373 2009 1341 1351
11. F. Malekzadeh, T. Marshall, and A. Pourshams A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors Int J Clin Pract 64 2010 1220 1227
12. E.S. Soliman, S. Mendis, and W.P. Dissanayake A polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization Trials 12 2011 3
13. P.I.L.L. Collaborative Group, A. Rodgers, and A. Patel An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk PLoS One 6 2011 e19857
14. D.S. Wald, J.K. Morris, and N.J. Wald Randomized polypill crossover trial in people aged 50 and over PLoS One 7 2012 e41297
15. S. Yusuf, P. Pais, and A. Sigamani Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the second Indian Polycap Study (TIPS-2) Investigators Circ Cardiovasc Qual Outcomes 5 2012 463 471
16. T.R. Fleming, and D.L. DeMets Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125 1996 605 613
17. Jaykaran Surrogate end points and their role in clinical trial Indian J Pharmacol 41 2009 54
18. J.A. Sterne, A.J. Sutton, and J.P. Ioannidis Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials BMJ 343 2011 d4002
19. Cochrane Collaboration Open Learning Material. Available from: http://www.cochrane-net.org/openlearning/HTML/mod0-3.htm; Accessed 07.06.13.